Azithromycin has been widely evaluated for its efficacy against COVID-19. The study by Timothy S C Hinks and colleagues1 adds value to the current literature, and we would like to share our comments.

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium, and ...

Pathogen diagnostics are strong determinants of azithromycin effects on diarrhea duration, but host factors may better predict benefits for severe outcomes. In this work, authors utilise a machine ...

Latest medical research on lung disease. Learn about the symptoms of chronic obstructive pulmonary disease (COPD), emphysema, and lung cancer along with the latest treatment information.

NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD Sergey N. Avdeev Viliya V. Gaynitdinova Qingyun Ma Research Open Access 01 Jul 2025 Scientific Reports Volume: 15, P: 21169 ...